SEC Tracker
Get the app

PDS Biotechnology PDSB

PDS Biotechnology (PDSB) filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational activities during the quarter. The filing highlights the company's progress in advancing its pipeline of innovative cancer immunotherapies, which is of key interest to investors tracking the development of PDS Biotechnology's promising therapeutic candidates.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when PDS Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  2. Medicinova MNOV public float $62M, Jun 30, 2025
  3. iBio IBIO public float $58M, Dec 31, 2025
  4. Lifevantage LFVN public float $64M, Dec 31, 2025
  5. Veru VERU public float $64M, Mar 31, 2025, over 18 months old